CD70 and cancer: In fact, the axis has the potential to induce expansion of effector T cells, break tolerance, and activate response in non-immunogenic tumors; several drugs—such as Varlilumab, SGN-CD70, SGN-7, and MDX-1203—targeting the CD27–CD70 axis are currently being tested in cancer therapy [44,53].